STA
PDLI

Summit Trail Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Summit Trail Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,336
Closed -$7K – 2139
2017
Q4 		$7K Buy
+2,336
New +$7.17K ﹤0.01% 1342

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Summit Trail Advisors's PDLI Position: Q1 2018 in Review

Summit Trail Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q1 2018, closing a stake of 2,336 shares — an estimated $7K sold.

Summit Trail Advisors first reported a position in PDLI in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 176 funds tracked by Wall St. Rank hold PDLI as of Q1 2018.

  • Summit Trail Advisors reported no remaining PDL BioPharma, Inc. position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 2,336 PDL BioPharma, Inc. shares in Q1 2018, an estimated $7K.
  • Summit Trail Advisors first reported a position in PDL BioPharma, Inc. in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's PDL BioPharma, Inc. position peaked at $7K in Q4 2017.
  • 176 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.